Vulvodynia

Vulvodynia is defined by the 2015 consensus of the International Society for the Study of Vulvovaginal Disease (ISSVD), the International Society for the Study of Women's Sexual Health (ISSWSH), and the International Pelvic Pain Society (IPPS) as "vulvar pain of at least 3 months' duration, without clear identifiable cause, which may have potential associated factors."^[1] That definition does real work in three parts: a minimum duration (distinguishing it from acute, self-limited vulvar pain), the absence of a clear identifiable cause (making this fundamentally a diagnosis of exclusion, reached only after infectious, dermatologic, neoplastic, neurologic, traumatic, iatrogenic, and hormonal causes have been actively ruled out - see Assessment & Diagnosis and Red Flags/Refer), and an acknowledgment that multiple factors may nonetheless be associated with a given patient's pain without any one of them being the sole "cause."^[1]

This exclusion process, and the diagnosis it leads to, deserve to be taken seriously rather than treated as a residual label applied once a clinician has run out of other ideas. Vulvodynia has a genuinely long history of being dismissed or mischaracterized. The 2015 consensus paper itself catalogues over a century of shifting, often dismissive terminology for the same underlying symptom complex - "satyriasis in females" (first century AD), "excessive hypersensibility of the nerves" (1880), "psychosomatic vulvovaginitis" (1978) - before the field converged on "vulvodynia" and, more recently, on today's biopsychosocial, multifactorial framework.^[1]

That history is not merely academic. In a population-based study of the greater Boston area, roughly 16% of women reported a history of chronic vulvar burning, knife-like pain, or pain on contact lasting three months or longer, and nearly 7% were experiencing it at the time of the survey - yet almost 40% of affected women never sought treatment at all, and of those who did, 60% saw three or more clinicians, many of whom were unable to provide a diagnosis.^[2] A later, larger population-based study across two U.S. metropolitan regions found that 7-8% of women had vulvar pain consistent with vulvodynia by age 40, and - critically - found that having access to health care did not meaningfully close this gap: more than half of women who sought care for their symptoms, even with good health care access, received no diagnosis.^[3] Hispanic women were found to be at meaningfully higher risk of developing symptoms in both studies.^[2][3] This pattern of delay and dismissal is a genuinely important part of the clinical picture, not a historical footnote - and naming it directly to an affected patient, alongside a clear, validating explanation of what vulvodynia is, is itself a real part of treatment (see Treatment Targets and Non-Pharmacologic Treatment).^[4]

Vulvodynia also overlaps substantially with other chronic pain conditions - fibromyalgia, irritable bowel syndrome, temporomandibular disorder, and interstitial cystitis/bladder pain syndrome (IC/BPS) chief among them, with orofacial pain showing an especially strong association.^[1] In one case-control study cited in the consensus terminology, almost all patients with IC/BPS also had comorbid vulvodynia - a genuinely striking overlap this chapter deliberately does not re-derive, since the Interstitial Cystitis chapter already covers the shared chronic-pelvic-pain-syndrome framework and neuropathic pharmacotherapy toolkit in detail (see Choose Initial Treatment and Special Populations).^[1]

What patients describe

Vulvar burning is the classic descriptor, but patients also report stinging, rawness, irritation, throbbing, or a sharp, knife-like pain. On examination, the vulva and vestibule characteristically look entirely normal - this is the expected finding in vulvodynia, not evidence that the pain is not real, and framing it that way to a patient is one of the more damaging, and unfortunately common, communication errors in this condition (see Common Errors to Avoid).

The classification that organizes this whole chapter

The 2015 consensus terminology classifies vulvodynia along four independent descriptor axes, and getting this classification right at the first visit genuinely changes both the workup and the treatment plan that follows.^[1]

The cotton-swab (Q-tip) test

For suspected localized disease, gently touch the vestibule with a cotton swab at multiple points around its circumference (commonly the 2, 4, 6, 8, and 10 o'clock positions and the posterior fourchette), asking the patient to rate any pain at each point. Pain reproducibly confined to the vestibule (medial to Hart's line) supports localized PVD; pain that is more diffuse, or present well beyond the vestibule, points toward generalized vulvodynia instead. Palpate the pelvic floor muscles directly as part of the same examination - pelvic floor muscle hypertonicity and other dysregulation is demonstrated in controlled studies of women with PVD and is a genuinely common, treatable contributor addressed in its own right below (see Choose Initial Treatment and Non-Pharmacologic Treatment).^[1]

The 2015 consensus terminology's appendix of "potential associated factors" is the most current, evidence-graded list available, and it deliberately frames vulvodynia as a likely multifactorial condition rather than one with a single cause - a given patient may have more than one of these factors contributing at once.^[1]

• Comorbidities and other pain syndromes - painful bladder syndrome/IC-BPS, fibromyalgia, irritable bowel syndrome, and temporomandibular disorder are all significantly associated, with orofacial pain showing an especially strong association; comorbidity with more than one such condition is common.^[1]
• Genetics - a genetic predisposition to PVD has been proposed through at least three overlapping mechanisms: polymorphisms increasing susceptibility to candidiasis or other infection, genetic variation permitting prolonged or exaggerated inflammatory responses, and increased susceptibility to hormonal changes associated with combined hormonal contraceptives (androgen receptor gene polymorphisms specifically).^[1]
• Hormonal factors - use of combined hormonal contraceptives has been associated with an increased risk of developing PVD in more than one study, though not universally replicated; ask specifically whether symptom onset lines up with starting a hormonal contraceptive (see Special Populations).^[1]
• Inflammation - increased inflammatory cells, mast cells, and subepithelial heparanase activity have been demonstrated in painful vestibular tissue, alongside an impaired ability to downregulate proinflammatory cytokine activity in some affected women.^[1]
• Musculoskeletal factors - pelvic floor muscle overactivity/hypertonicity, myofascial dysfunction, and biomechanical imbalance are demonstrated in controlled studies of women with PVD and are among the more directly treatable associated factors (see Choose Initial Treatment).^[1]
• Neurologic mechanisms - both central (women with PVD show heightened sensitivity to stimulation even at non-genital sites such as the forearm, alongside brain imaging changes in structure and function) and peripheral (increased vestibular nerve fiber density, with these nerve endings showing features of sensitized nociceptors) mechanisms have been demonstrated.^[1]
• Psychosocial factors - anxiety, depression, childhood victimization, and posttraumatic stress are population-level risk factors for developing vulvodynia, not merely consequences of living with it; the odds of vulvodynia were found to be four times higher among women with an antecedent mood or anxiety disorder. Pain catastrophizing, fear of pain, hypervigilance, low pain self-efficacy, and avoidance are all associated with greater pain intensity or sexual dysfunction once the condition is present.^[1]
• Structural defects - pelvic organ prolapse has been associated with vulvar and pelvic pain in some patients, with small case series reporting resolution of vulvodynia after surgical prolapse correction; this is the lowest-evidence-grade associated factor in the consensus appendix.^[1]
• Ethnicity - Hispanic women have been found, in more than one large population-based study, to be at meaningfully higher risk of developing vulvodynia symptoms than white or Black women.^[2][3]

History

Document duration (the case definition requires at least three months), and work through all four classification axes directly: location (localized/vestibular versus generalized), provocation (what specifically triggers the pain, and whether it is provoked, spontaneous, or both), onset (primary since first tampon/intercourse, or secondary after a period of comfort), and temporal pattern.^[1] Ask specifically about the relationship between symptom onset and starting or stopping a combined hormonal contraceptive, about urinary and bowel symptoms (given the genuine overlap with IC/BPS and irritable bowel syndrome), about a history of anxiety, depression, or trauma (screened for in a trauma-informed, non-judgmental manner, given how strongly these are associated - see Risk Factors), and about the impact on sexual function and the patient's relationship, since this impact is real and deserves to be asked about directly rather than left for the patient to raise unprompted.^[1][4]

Physical examination

• Begin with careful visual inspection before any contact - the vulva and vestibule should look grossly normal in vulvodynia; any lesion, plaque, erosion, discoloration, or architectural change is itself a red flag pointing toward a specific dermatosis or other identifiable cause instead (see Red Flags/Refer).
• Perform the cotton-swab (Q-tip) test systematically around the vestibule to map the location and severity of provoked pain, and to distinguish localized from generalized disease (see Recognize the Condition).
• Palpate the pelvic floor muscles directly (levator ani, obturator internus) for hypertonicity, taut bands, or trigger points - a genuinely common, treatable contributor that is easy to miss without deliberately looking for it.^[1]
• A single-digit or speculum exam, performed gently and with the patient's explicit consent and control over pacing, can help assess for deeper pelvic floor or organ-related tenderness once vestibular findings are documented; avoid escalating to a full exam that reproduces severe pain without clear diagnostic benefit.

Laboratory and adjunct testing

Wet mount, vaginal pH, and a yeast culture (not simply a bedside potassium hydroxide prep, which can miss non-albicans species) to exclude infection - this is genuinely essential given how much symptom overlap exists between recurrent candidiasis and vulvodynia. Consider patch testing when a specific product or topical exposure is suspected as a contact allergen or irritant. Biopsy is not a routine part of vulvodynia diagnosis - by definition, the tissue looks normal - and should be reserved for any lesion, pigmented area, or finding suggestive of a specific dermatosis or neoplasm, following the same biopsy-indication framework detailed in the Lichen Sclerosus chapter rather than a separate one here.

Differential diagnosis

The current consensus terminology's first category - "vulvar pain caused by a specific disorder" - is the working differential list for every new presentation, and a patient can genuinely have both a specific disorder (for example, lichen sclerosus) and vulvodynia at the same time, so finding one does not automatically exclude the other.^[1]

Once these are reasonably excluded (or identified and treated in their own right, alongside vulvodynia where both coexist), and pain has persisted three months or more without full explanation by any of the above, vulvodynia is the appropriate diagnosis.^[1]

• Reduce spontaneous and/or provoked vulvar pain, and specifically reduce pain with contact - intercourse, tampon use, tight clothing, prolonged sitting - to the extent the patient's subtype allows.
• Restore comfortable sexual function and non-sexual daily activities, without treating either as less important than the other.
• Directly address pelvic floor muscle hypertonicity where present, since this is a genuinely common and treatable contributor rather than an incidental finding (see Choose Initial Treatment).^[1]
• Treat the real psychosocial and relationship impact of this condition - anxiety, depression, sexual avoidance, and relationship strain - as a core treatment target in its own right, not as secondary to "the real physical problem."^[1][4]
• Explain the diagnosis and treatment plan clearly, and set realistic expectations: rapid resolution is unusual even with appropriate therapy, and a multidisciplinary approach is not a sign the clinician doubts the pain is real - patients may otherwise perceive it that way, and saying this plainly, up front, is itself part of good care.^[4]
• Match treatment to the patient's specific subtype and associated factors (localized versus generalized, provoked versus spontaneous, hormonal or musculoskeletal contributors) rather than applying one uniform protocol to every patient (see Choose Initial Treatment).^[1]
• Coordinate care across disciplines - physical therapy, pain psychology/sex therapy, and pharmacotherapy - as a treatment target in itself, since the evidence base most strongly supports combination rather than single-modality treatment (see Non-Pharmacologic Treatment).^[4]

First-line for every patient - education, validation, and vulvar skin care

Explain the diagnosis clearly, validate that the pain is genuinely physical even though the exam looks normal, and set realistic expectations about the treatment timeline (see Treatment Targets).^[4] Pair this with basic vulvar skin care: stop soap and fragranced products on the area, use a plain fragrance-free emollient as a soap substitute and moisturizer, choose breathable cotton underwear, and avoid known personal irritants and prolonged occlusion or friction - the same principles used for other chronic vulvar conditions in this platform (see the Lichen Sclerosus chapter's Non-Pharmacologic Treatment section).

Topical lidocaine - first-line for localized, provoked vestibulodynia

Lidocaine 5% ointment can be used two ways, often together: applied nightly with a cotton ball left in place overnight to build tolerance to touch over time (an "overnight lidocaine" protocol), and/or applied to the vestibule roughly 15-20 minutes before anticipated contact (intercourse, a gynecologic exam) for situational relief. A meaningful, reproducible pain reduction with topical lidocaine also helps confirm that the pain generator is genuinely peripheral and vestibule-localized, supporting the localized-PVD classification.

Pelvic floor physical therapy - for hypertonicity, in either subtype

Pelvic floor muscle overactivity/hypertonicity is a genuinely common, treatable contributor in vulvodynia, and physical therapy is viewed as an effective first-line intervention wherever it is present, whether the vulvodynia itself is localized or generalized.^[1] A 2017 systematic review identified 43 eligible studies (7 randomized controlled trials, 20 prospective studies, 5 retrospective studies, 6 case reports, and 6 study protocols) evaluating biofeedback, vaginal dilators, electrical stimulation, patient education, and multimodal or multidisciplinary physical therapy approaches; the large majority showed physical therapy modalities effective for decreasing pain during intercourse and improving sexual function, though the authors were candid that methodological limitations (small samples, inconsistent comparison groups) mean this positive signal still needs confirmation in more robust, well-designed randomized trials.^[7] Avoid defaulting to generic pelvic-floor-strengthening (Kegel) exercises without first assessing tone - strengthening an already hypertonic, painful pelvic floor can worsen rather than improve symptoms, exactly the same caution detailed for interstitial cystitis/bladder pain syndrome in that chapter's own Choose Initial Treatment section.

Oral neuropathic pharmacotherapy - the backbone for generalized disease, an adjunct for localized disease

Tricyclic antidepressants (amitriptyline typically first, nortriptyline or desipramine as less anticholinergic/sedating alternatives), gabapentin, and pregabalin are used following the same low, chronic-pain-range dosing principle already detailed for amitriptyline in the Interstitial Cystitis chapter - this chapter deliberately does not repeat that dosing and titration guidance rather than re-deriving it. Duloxetine or venlafaxine are reasonable alternatives, particularly when a coexisting mood disorder is also being treated. Topical compounded formulations (for example, amitriptyline combined with baclofen or with gabapentin in a compounded cream) are used in some specialized vulvar pain clinics for localized disease, though the comparative trial evidence for these specific compounded combinations remains limited relative to the individual oral agents.

Hormonal therapy - for a suspected hormonal contributor

When secondary PVD onset lines up temporally with starting a combined hormonal contraceptive, discuss stopping the contraceptive and consider a trial of topical vaginal/vestibular estrogen, sometimes combined with compounded topical testosterone, as a targeted intervention for this specific associated factor rather than treating every patient with the same generic protocol.^[1] In postmenopausal or lactating patients, confirm first whether genitourinary syndrome of menopause or lactational hormonal deficiency - both specific, identifiable, separately treatable causes - better explains the picture before treating as vulvodynia (see Special Populations).

Pelvic-floor-hypertonicity-directed adjuncts - refractory disease, specialist-directed

For hypertonicity that persists despite physical therapy, compounded vaginal diazepam suppositories, compounded topical baclofen, or pelvic floor injection of onabotulinumtoxinA are recognized off-label, specialist-directed options.

Psychological support and sex therapy - core, not adjunct

Cognitive-behavioral therapy directly targeting pain catastrophizing, fear-avoidance, and hypervigilance, along with sex therapy addressing the relationship and intimacy impact, are supported by the same landmark randomized trial that established vestibulectomy's efficacy (see below): group CBT performed comparably to biofeedback, and both produced durable improvement in pain, psychological adjustment, and sexual function.^[5] This should be offered proactively as part of an individualized plan, not reserved as a last resort after pharmacologic and physical therapy have already been tried (see Treatment Targets).^[4]

Surgical vestibulectomy - for refractory, localized, provoked vestibulodynia specifically

Vestibulectomy (surgical excision of the affected vestibular tissue) is a genuine, evidence-supported option - not a last-resort measure reflecting a failure of conservative care - specifically for well-characterized localized, provoked vestibulodynia that has not responded to an adequate trial of conservative management. In the landmark randomized trial comparing vestibulectomy with group CBT and with biofeedback, all three treatments improved pain, psychological adjustment, and sexual function, but vestibulectomy produced the largest reduction in cotton-swab-test pain at six months (about a 70% reduction, versus about 29% with CBT).^[5] At two-and-one-half-year follow-up, gains from all three treatments were largely maintained, and vestibulectomy retained roughly twice the pain reduction of the behavioral treatments.^[8] A 2024 systematic review of 29 surgical outcome studies found success rates (defined as significant dyspareunia reduction) ranging from 52% to 93%, sexual function improvement in 57-87% of patients, and patient satisfaction of 79-93%; Bartholin gland cyst formation was the most frequent complication, occurring in up to about 9% of patients.^[6] Not indicated for generalized or spontaneous vulvodynia - the evidence base specifically supports the localized, provoked subtype, and surgery should follow, not replace, a genuine trial of conservative therapy and diagnostic confirmation of subtype.^[5][6]

Vulvar skin care and irritant avoidance

• Stop soap, fragranced washes, wipes, panty liners, and any other potential irritant on the vulva; use a plain, fragrance-free emollient as a soap substitute.
• Choose loose-fitting, breathable cotton underwear, and avoid prolonged occlusion or friction from tight clothing.
• Avoid unproven home remedies (tea tree oil and similar topical "natural" treatments in particular) which can themselves cause irritant or allergic contact dermatitis and worsen symptoms.

Pelvic floor physical therapy in practice

Manual therapy (myofascial release, trigger-point release), biofeedback, progressively sized vaginal dilator therapy, and a home relaxation/lengthening program (diaphragmatic breathing, deliberately relaxing rather than contracting the pelvic floor - the opposite of a Kegel) are the core components, matched to what the individual exam finds.^[7] Avoid starting with isolated pelvic-floor-strengthening exercises before hypertonicity has been assessed and addressed - this can worsen pain in an already overactive pelvic floor.

Sexual health and relationship support

Discuss lubricant use, pacing and timing intercourse around symptom flares, pelvic floor relaxation techniques before penetration, and non-penetrative intimacy as a legitimate option while treatment is underway, not a consolation prize. The relationship and psychosocial burden of this condition is real and common, and deserves direct, unhurried conversation rather than being treated as a secondary concern once "the real pain" is addressed.^[1][4]

Psychological support and cognitive-behavioral therapy

Target pain catastrophizing, fear of pain, hypervigilance, and avoidance directly - all specifically identified psychosocial factors associated with greater pain intensity and sexual dysfunction in vulvodynia.^[1] Group CBT produced pain, psychological, and sexual-function improvements comparable to biofeedback in a randomized trial, both durable to two-and-one-half years of follow-up - genuine, guideline-level evidence that this is a core treatment, not a soft adjunct.^[5][8]

Communication and validation

State plainly, early in the relationship with the patient, that a normal-appearing exam does not mean the pain is not real, that a multidisciplinary approach reflects the genuinely multifactorial nature of this condition rather than any doubt about the patient's experience, and that the historical pattern of diagnostic delay and dismissal documented in the literature is a real, acknowledged problem - not something happening only to this particular patient.^[2][3][4]

Adolescents and young women

Primary PVD - pain present since the first attempted tampon use or first intercourse - is a genuine, common presentation in this age group and should not be minimized as anxiety about sexual inexperience or dismissed as something the patient will "grow out of." Topical lidocaine and pelvic floor physical therapy are reasonable, low-risk first steps; involve the patient directly in decision-making with appropriate privacy and confidentiality, and involve a caregiver only to the extent the patient is comfortable with.

Women using or considering combined hormonal contraception

Ask specifically whether symptom onset (particularly a secondary onset after previously pain-free intercourse or tampon use) lines up temporally with starting a combined hormonal contraceptive - this is a specific, actionable associated factor, not a coincidence to overlook.^[1] A trial of stopping the contraceptive, alongside topical vaginal/vestibular estrogen with or without compounded testosterone, is a reasonable, targeted next step (see Choose Initial Treatment).

Postmenopausal women

Distinguish vulvodynia from genitourinary syndrome of menopause (vulvovaginal atrophy) - both can present with vulvar discomfort, but atrophy is a specific, identifiable, hormonally-driven cause with its own dedicated treatment (topical vaginal estrogen), and treating it as vulvodynia, or vice versa, delays effective care for whichever condition is actually present. The two can also coexist.^[1]

Pregnancy and lactation

Lactational-amenorrhea-associated vulvovaginal dryness and discomfort is itself a specific, identifiable hormonal-deficiency cause in the current terminology, distinct from vulvodynia, and often responds to vaginal moisturizers or, once appropriate, a return of estrogen with weaning.^[1] Where oral neuropathic pharmacotherapy is genuinely needed during pregnancy or lactation, individualize the choice with obstetric input and favour the lowest-risk, most reversible options first - education, vulvar skin care, topical lidocaine, and pelvic floor physical therapy.

Patients with significant psychiatric or trauma comorbidity

Given the population-level association between antecedent mood/anxiety disorders, childhood victimization, posttraumatic stress, and the later development of vulvodynia, screen directly and in a trauma-informed manner.^[1] Use a gentle, patient-paced examination technique - offer to defer or stage the exam, use the smallest appropriate speculum, and give the patient explicit control over pacing - and involve pain psychology proactively as part of the initial plan rather than only after pharmacologic therapy has failed (see Choose Initial Treatment).

Patients with comorbid chronic overlapping pain conditions

Fibromyalgia, irritable bowel syndrome, temporomandibular disorder, and especially interstitial cystitis/bladder pain syndrome are all significantly associated with vulvodynia, and in one study nearly all patients being evaluated for IC/BPS also had comorbid vulvodynia.^[1] Consider whether a single, coordinated treatment plan addressing both bladder and vulvar pain - shared neuropathic pharmacotherapy, shared pelvic floor physical therapy - makes more sense than treating each in isolation; see the Interstitial Cystitis chapter for that condition's own diagnostic and treatment detail.

Patients being considered for vestibulectomy

Confirm the subtype is genuinely localized and provoked, and confirm an adequate, well-documented trial of conservative therapy (topical lidocaine, pelvic floor physical therapy, and typically oral pharmacotherapy) has already been tried before referring.^[5][6] Set expectations using the actual trial data - meaningful but not universal success, with Bartholin gland cyst formation as the most common complication - rather than presenting surgery as either a guaranteed cure or a last-resort failure of care.^[6]

• Reassess pain using a consistent method at each visit - a simple 0-10 scale, and for localized disease, a repeat cotton-swab test - to track objective response rather than relying on vague overall impressions.
• Reassess sexual function and psychosocial impact directly at follow-up, not only physical pain scores - these are core treatment targets in their own right (see Treatment Targets).^[4]
• For patients on oral tricyclic, gabapentinoid, or SNRI therapy: check tolerability and titrate as needed, following the same monitoring principles already detailed for amitriptyline in the Interstitial Cystitis chapter.
• For patients in pelvic floor physical therapy: reassess pelvic floor tone and trigger points periodically, and confirm adherence to the home program between visits.
• For patients who have had a vestibulectomy: routine postoperative wound follow-up, with attention to delayed healing or Bartholin gland cyst formation, the most frequently reported complication.^[6] Continued pelvic floor physical therapy after surgery is often still appropriate, since surgery addresses the peripheral, anatomic pain generator but not necessarily an already-established pattern of pelvic floor guarding or central sensitization.
• Reassess the diagnosis and subtype itself if response remains poor despite an adequate multimodal trial, rather than continuing to escalate the same approach indefinitely (see Red Flags/Refer and Treatment Failure/Next Step).

1. Confirm the diagnosis and subtype are actually correct before escalating - treating localized disease as though it were generalized, or vice versa, is a genuinely common and avoidable source of apparent treatment failure.^[1]
2. Education, validation, and vulvar skin care not controlling symptoms after an adequate trial: add topical lidocaine for localized disease, and/or start pelvic floor physical therapy if hypertonicity is present on exam.
3. Topical therapy and/or physical therapy alone insufficient, particularly in generalized disease or with a clear neuropathic/central-sensitization component: add oral pharmacotherapy - a tricyclic antidepressant is typically favoured first, with gabapentin/pregabalin or an SNRI as alternatives.
4. Persistent, significant psychosocial impact or sexual dysfunction despite the above: refer for formal cognitive-behavioral therapy and/or sex therapy - this is a core escalation step with genuine trial-level evidence behind it, not a last resort.^[5][8]
5. A suspected hormonal contributor not yet addressed (secondary PVD onset temporally linked to a hormonal contraceptive, or perimenopausal/lactational timing): trial stopping the contraceptive and/or topical vaginal/vestibular estrogen, with or without compounded testosterone.
6. Refractory pelvic floor hypertonicity despite an adequate physical therapy trial: consider compounded topical baclofen, compounded vaginal diazepam, or pelvic floor onabotulinumtoxinA injection, specialist-directed.
7. Well-characterized, refractory localized, provoked vestibulodynia despite an adequate multimodal conservative trial: refer for consideration of vestibulectomy - a genuine, evidence-supported option at this stage, not a failure of prior care.^[5][8][6]
8. At any point, a new lesion, ulcer, or other atypical finding should prompt reassessment for a specific identifiable cause (see Red Flags/Refer) rather than continued escalation of vulvodynia-directed therapy.

• Diagnosing vulvodynia without first excluding infection, a specific dermatosis, or another identifiable cause - this is fundamentally a diagnosis of exclusion, and skipping the exclusion step is a genuine, avoidable error.^[1]
• Telling a patient, directly or by implication, that a normal-appearing exam means the pain is not real - a normal exam is the expected finding in vulvodynia, not evidence against the diagnosis, and this exact pattern of dismissal is well documented as contributing to real diagnostic delay.^[2][3]
• Treating every patient with the same protocol rather than classifying localized versus generalized and provoked versus spontaneous disease first - this classification genuinely changes both workup and treatment, most importantly whether surgery is even a relevant future option.^[1]
• Offering or referring for vestibulectomy in generalized or spontaneous vulvodynia - the surgical evidence base specifically supports localized, provoked disease.^[5][6]
• Recommending generic pelvic-floor-strengthening (Kegel) exercises by default without first assessing pelvic floor tone - worsening an already hypertonic, painful pelvic floor is a real, avoidable harm.
• Treating the psychosocial and relationship impact as secondary to "the real physical pain" rather than as a core treatment target with its own genuine trial-level evidence for CBT and sex therapy.^[5][8]
• Missing a hormonal contributor by not asking directly whether symptom onset lined up with starting a combined hormonal contraceptive.^[1]
• Conflating vulvodynia with genitourinary syndrome of menopause or lactational hormonal deficiency in the right clinical context, rather than treating the identifiable hormonal cause on its own terms.^[1]
• Abandoning an adequately dosed pharmacologic or physical therapy trial too early, before giving it the weeks-to-months typically needed to judge response.
• Framing a multidisciplinary referral as a sign the pain is being disbelieved, rather than explaining upfront that this reflects the genuinely multifactorial nature of the condition.^[4]

How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

Topical Neuropathic-Pain Therapy (First-Line for Localized Provoked Vestibulodynia)

Used alone for localized disease, or as an adjunct while oral therapy is titrated in generalized disease.

Oral Neuropathic-Pain Pharmacotherapy (Backbone for Generalized Vulvodynia, Adjunct for Localized Disease)

Follows the same low, chronic-pain-range dosing principle detailed for amitriptyline in the Interstitial Cystitis chapter; not repeated here.

Hormonal Therapy for Suspected Hormonally-Mediated Disease

Targeted at a specific associated factor - a confirmed hormonal history (combined hormonal contraceptive-associated secondary PVD, genitourinary syndrome of menopause, or lactational deficiency) - rather than a general vulvodynia therapy.

Pelvic-Floor-Hypertonicity-Directed Adjuncts (Off-Label, Specialist-Directed)

Reserved for hypertonicity that persists despite an adequate pelvic floor physical therapy trial.